知镜 Cognispect · 医学文献与研究工作台

Prognostic Comparison of Breast Neuroendocrine Neoplasms and Invasive Ductal Carcinoma With Neuroendocrine Differentiation: A Pathology-Reviewed Cohort and Population-Based Analysis.

Shi X, Yao Z, Zhou Q, Wen Y, Zhai Y, Wang D, Liu J, Zhang B.
Cancer medicine · 2026-11-01 · PMID 43016040

文献摘要

Background Breast neuroendocrine neoplasms (Br-NENs) are rare breast tumors with substantial clinicopathological heterogeneity. The prognostic implications of the 2019 World Health Organization (WHO) classification remain incompletely characterized. This study aimed to evaluate the prognostic significance of true breast neuroendocrine neoplasms (NENs) and invasive ductal carcinoma with neuroendocrine differentiation (IDC-NE) under the 2019 WHO framework. Methods We retrospectively analyzed a pathology-reviewed single-center cohort of 123 patients, of whom 121 were included in survival analyses, and a separate population-based cohort of 498 patients from the Surveillance, Epidemiology, and End Results (SEER) database. Institutional cases were reassessed according to the 2019 WHO criteria, whereas SEER tumor groups were defined using registry-reported International Classification of Diseases for Oncology, Third Edition (ICD-O-3) morphology codes. Survival outcomes were compared using Kaplan-Meier analysis and Cox proportional hazards models. Sensitivity analyses were performed to assess robustness, while exploratory propensity score matching (PSM) analyses compared IDC-NE with conventional invasive ductal carcinoma (IDC). Results In the single-center cohort, true NENs showed more aggressive clinicopathological features and were associated with poorer survival than IDC-NE. In the SEER cohort, 498 patients were included, comprising 323 with registry-defined NEN and 175 with registry-defined IDC-NE. NEN showed more aggressive characteristics, including a higher rate of distant metastasis at diagnosis. After adjustment for age, stage, year of diagnosis, and race, registry-defined NEN was independently associated with worse overall survival (hazard ratio [HR] = 1.62, 95% confidence interval [CI] 1.14-2.32) and breast cancer-specific survival (HR = 2.00, 95% CI 1.30-3.06). Sensitivity analyses yielded consistent results. Conclusion Breast NENs were associated with poorer outcomes than IDC-NE in the pathology-reviewed cohort. The SEER analysis provided complementary population-based prognostic evidence for registry-defined tumor groups. Exploratory PSM analyses did not identify a statistically significant survival difference between IDC-NE and conventional IDC.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。